PIK3CA and neoplasm: This was well demonstrated by significant in vivo and ex vivo anti-tumor effect in PIK3CA-mutated PDXs, which acquired resistance over time upon exposure to PI3Ki as well as PK3CA-WT PDXs treated with combination therapy.